With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
SNY trades against a final fair-value range of $46.92-$57.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Top-line growth stagnates near 1% as the pipeline fails to offset competitive pressures across core segments. With the payout ratioPayout ratioDividends per share divided by EPS. Measures how much of earnings the company distributes versus retains for reinvestment. already at 97.73%, any margin contraction creates severe risk of a dividend freeze or cut. Valuation multiple remains trapped.
Operating margin dips below the 20.00% trailing average, compressing available free cash flow.
The 97.73% payout ratio forces a dividend cut due to unexpected top-line stagnation near 1%.
Pipeline fails to offset competitive pressures across core immunology and oncology commercial segments.
| Line item | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|
| Revenue | $40.56B | $41.62B+2.6% | $44.29B+6.4% | $46.72B+5.5% | +4.8% |
| Gross profit | $28.68B | $28.99B | $31.08B | $33.67B | +5.5% |
| Operating income | $10.93B | $8.69B | $8.92B | $9.60B | -4.2% |
| Net income | $8.37B | $5.40B-35.5% | $5.56B+3.0% | $7.81B+40.5% | -2.3% |
| EPS (diluted) | $2.69 | $2.16 | $2.30 | $3.20 | +6.0% |
| EBITDA | $13.51B | $11.32B | $10.99B | $12.48B | -2.6% |
| R&D | $6.50B | $6.51B | $7.39B | $7.84B | +6.5% |
| SG&A | $8.74B | $9.48B | $9.82B | $10.24B | +5.4% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| Increases in the payout ratio above current 97.73%. | Monitor | Deterioration versus the report thesis |
| Deterioration of OCF to Net Income ratio below 1.0x. | Monitor | Deterioration versus the report thesis |
